In This Article:
Atossa Therapeutics (ATOS) announced data describing the discovery of compounds that may be synergistic with (Z)-endoxifen and that could potentially be used in combinations for the treatment of breast cancer. The data is being presented in a poster at the 2024 San Antonio Breast Cancer Symposium, SABCS, on December 13, 2024. The data suggest that combination therapies with (Z)-endoxifen and agents targeting topoisomerase, CDK, mTOR/PI3K and AKT have potential in the treatment of breast cancer but require further study.
Pick the best stocks and maximize your portfolio:
-
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
-
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATOS: